Abeona Therapeutics to Present at Piper Jaffray 27th Annual Healthcare Conference
NEW YORK, NY -- (Marketwired) -- 12/01/15 -- Abeona Therapeutics, Inc. (NASDAQ: ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Tim Miller, Ph.D., President and CEO, will be presenting for the company at the Piper Jaffray 27th Annual Healthcare Conference in New York City, NY on Wednesday, December 2nd, 2015 at 10am ET on Track 2 at The Palace Hotel in NYC.
Event: Piper Jaffray 27th Annual Healthcare Conference 2015
Date: Tuesday, December 2nd, 2015
Time: 10:00am EST
Location: The Palace Hotel, New York City
Room: Hubbard 1
Webcast Link: http://edge.media-server.com/m/p/t8kfimt6
The presentation will be open to all interested investors through a live audio webcast accessible from http://edge.media-server.com/m/p/t8kfimt6. An archived replay of the webcast will also be available for 90 days following the live presentation.
About Piper Jaffray:
Piper Jaffray's Healthcare Conference will feature nearly 300 of the most highly regarded and influential companies in the biotechnology, specialty pharmaceuticals, medical technology, medical diagnostics, life science tools and healthcare services sectors. Industry experts, physicians and academicians have also been invited to host panels and address regulatory, reimbursement and legal issues. Discussions about gene therapy and orphan diseases will provide additional clarity to interested investors.
About Abeona: Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.
Company and Media Contact:
VP of Communications
Abeona Therapeutics, Inc.
Source: Abeona Therapeutics
Released December 1, 2015